BioNTech (BNTX) is a publicly traded Healthcare sector company. As of November 17, 2026, BNTX trades at $85.28 with a market cap of $21.22B and a P/E ratio of 0.00. BNTX moved +0.03% today. Year to date, BNTX is -11.80%; over the trailing twelve months it is -17.28%. Its 52-week range spans $79.52 to $124.00. Analyst consensus is strong buy with an average price target of $121.21. Rallies surfaces BNTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioNTech to buy $205 million FDA voucher for late-stage oncology filing: BioNTech agreed to buy a US FDA Priority Review Voucher from Scholar Rock for $205 million in cash. The voucher will support a future filing for a late-stage oncology asset and shorten the target FDA review timeline; the deal is subject to Hart-Scott-Rodino clearance.
| Metric | Value |
|---|---|
| Price | $85.28 |
| Market Cap | $21.22B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 2.13% |
| 52-Week High | $124.00 |
| 52-Week Low | $79.52 |
| Volume | 13.05K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
16 analysts cover BNTX: 0 strong buy, 12 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $121.21.